US Edition
FDA Approves Tryptyr Eye Drops for Dry Eye Disease
- In 2025, Tryptyr, a new eye drop targeting dry eye disease, received regulatory approval in the United States.
- This approval followed limited existing treatments that have slow onset, poor adherence, and patient dissatisfaction.
- Tryptyr acts as a TRPM8 receptor agonist, stimulating corneal nerves to quickly increase natural tear production.
- Phase 3 trials involving over 930 patients showed Tryptyr increased tear production by 42.6% at day 14 compared to 8.2% for vehicle.
- Alcon plans to launch Tryptyr in the U.S. in the third quarter of 2025, offering a new direct treatment for tear deficiency in dry eye disease.
80 Articles
80 Articles
ABC FOX Montana
FDA Approves Tryptyr Eye Drops for Dry Eye Disease
MONDAY, June 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic solution) for the treatment of signs and symptoms of dry eye disease.
Bausch + Lomb Launches Two New Eye Drops in the U.S.
Bausch + Lomb Corporation announced the U.S. launch of Blink Nourish Lubricating eye drops and Blink Boost Lubricating eye drops. Both products are preservative-free, contact-lens friendly and uniquely formulated to provide hydration and comfort for dry eyes in a multi-dose bottle. Blink Nourish “Blink Nourish and Blink Boost deliver the same science-backed, long-lasting relief that consumers have come to rely on from our other Blink eye drop p…
Bausch + Lomb Launches Blink Nourish and Blink Boost Lubricating Eye Drops in the US
Bausch + Lomb announced the US launch of Blink Nourish and Blink Boost lubricating eye drops. According to B+L, both products are preservative-free, contact-lens friendly and uniquely formulated to provide hydration and comfort for dry eyes in a multi-dose bottle. "Blink Nourish and Blink Boost deliver the same science-backed, long-lasting relief that consumers have come to rely on from our other Blink eye drop products,” John Ferris, president,…
Coverage Details
Bias Distribution
- 50% of the sources are Center
To view factuality data please Upgrade to Premium